DDB2 and breast carcinoma: Although the clinical use of lapatinib is limited by the development of acquired resistance in breast cancers 54-56, we demonstrate that lapatinib binds directly to the DNA-binding region of DDB2, inhibits its chromatin association, and promotes proteasomal degradation, thereby enhancing the cytotoxic effects of DNA-damaging chemotherapy.